Whole-genome sequencing of 490,640 UK Biobank participants

dc.contributor.authorThe UK Biobank Whole-Genome Sequencing Consortium
dc.contributor.authorIllumina
dc.contributor.authorUK Biobank
dc.contributor.authorSanger (Velsera Seven Bridges)
dc.contributor.authorJohnson & Johnson
dc.contributor.authorGSK
dc.contributor.authorAmgen deCode genetics
dc.contributor.authorAstraZeneca
dc.contributor.authorManuscript Writing Group
dc.contributor.departmentDepartment of Engineering
dc.date.accessioned2026-10-02T11:04:00Z
dc.date.available2026-10-02T11:04:00Z
dc.date.issued2025-09-18
dc.descriptionPublisher Copyright: © The Author(s) 2025.en
dc.description.abstractWhole-genome sequencing provides an unbiased and complete view of the human genome and enables the discovery of genetic variation without the technical limitations of other genotyping technologies. Here we report on whole-genome sequencing of 490,640 UK Biobank participants, building on previous genotyping effort1. This advance deepens our understanding of how genetics associates with disease biology and further enhances the value of this open resource for the study of human biology and health. Coupling this dataset with rich phenotypic data, we surveyed within- and cross-ancestry genomic associations and identified novel genetic and clinical insights. Although most associations with disease traits were primarily observed in individuals of European ancestries, strong or novel signals were also identified in individuals of African and Asian ancestries. With the improved ability to accurately genotype structural variants and exonic variation in both coding and UTR sequences, we strengthened and revealed novel insights relative to whole-exome sequencing2,3 analyses. This dataset, representing a large collection of whole-genome sequencing data that is available to the UK Biobank research community, will enable advances of our understanding of the human genome, facilitate the discovery of diagnostics and therapeutics with higher efficacy and improved safety profile, and enable precision medicine strategies with the potential to improve global health.en
dc.description.versionPeer revieweden
dc.format.extent10
dc.format.extent3762461
dc.format.extent692-701
dc.identifier.citationThe UK Biobank Whole-Genome Sequencing Consortium, Illumina, UK Biobank, Sanger (Velsera Seven Bridges), Johnson & Johnson, GSK, Amgen deCode genetics, AstraZeneca & Manuscript Writing Group 2025, 'Whole-genome sequencing of 490,640 UK Biobank participants', Nature, vol. 645, no. 8081, pp. 692-701. https://doi.org/10.1038/s41586-025-09272-9en
dc.identifier.doi10.1038/s41586-025-09272-9
dc.identifier.issn0028-0836
dc.identifier.other251049069
dc.identifier.otherb7368e1e-228a-4fbb-b535-2b846f01794c
dc.identifier.other105016650839
dc.identifier.other40770095
dc.identifier.urihttps://hdl.handle.net/20.500.11815/8496
dc.language.isoen
dc.relation.ispartofseriesNature; 645(8081)en
dc.relation.urlhttps://www.scopus.com/pages/publications/105016650839en
dc.rightsinfo:eu-repo/semantics/openAccessen
dc.subjectMultidisciplinaryen
dc.titleWhole-genome sequencing of 490,640 UK Biobank participantsen
dc.type/dk/atira/pure/researchoutput/researchoutputtypes/contributiontojournal/articleen

Skrár

Original bundle

Niðurstöður 1 - 1 af 1
Nafn:
s41586-025-09272-9.pdf
Stærð:
3.59 MB
Snið:
Adobe Portable Document Format